Infliximab Use in Luminal Crohn's Disease

Gastroenterology Clinics of North America

Volumn 35, Issue 4, 2006, Pages 775-793

  Richter, James A ^a   Bickston, Stephen J ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIMETABOLITE; BCG VACCINE; BIOLOGICAL MARKER; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; DIPHENHYDRAMINE; DRUG ANTIBODY; ETANERCEPT; FAMOTIDINE; FUNGUS ANTIBODY; HYDROCORTISONE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; NEUTROPHIL CYTOPLASMIC ANTIBODY; PARACETAMOL; PREDNISONE; SACCHAROMYCES CEREVISIAE ANTIBODY; STEROID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ABDOMINAL ABSCESS; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSCESS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANUS FISTULA; APRAXIA; ARM; ARTHRALGIA; ARTHRITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BRONCHITIS; BRONCHOSPASM; CANDIDIASIS; CELLULITIS; CHEST TIGHTNESS; CHILL; CHOLESTASIS; CLINICAL PRACTICE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONFUSION; CONGESTIVE HEART FAILURE; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE RESISTANCE; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG INFUSION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EDEMA; EUROPE; FACE EDEMA; FACIAL NERVE PARALYSIS; GAIT DISORDER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAND EDEMA; HEALTH CARE COST; HEALTH PRACTITIONER; HEART FAILURE; HEPATITIS; HEPATITIS B; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; HYPOTENSION; IMMUNOLOGY; INFECTION; INFECTION PREVENTION; INTESTINE FISTULA; JAUNDICE; LARYNX EDEMA; LISTERIOSIS; LIVER FAILURE; LIVER TOXICITY; LONG TERM EXPOSURE; LUPUS LIKE SYNDROME; MAINTENANCE THERAPY; MEDICAL INFORMATION; MEDICAL LITERATURE; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; OPTIC NEURITIS; PARALYSIS; PARESTHESIA; PATHOGENESIS; PATIENT CARE; PEER GROUP; PHARYNGITIS; PHARYNX; PHYSICIAN; PNEUMOCYSTOSIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PREGNANCY OUTCOME; PREMEDICATION; PROGNOSIS; PRURITUS; PYODERMA GANGRENOSUM; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEIZURE; SEPSIS; SERUM SICKNESS; SINUSITIS; SMOKING; SORE THROAT; TOXICOKINETICS; TREATMENT OUTCOME; TUBERCULOSIS; UNITED STATES; URINARY TRACT INFECTION; URTICARIA; VIRUS INFECTION; VIRUS REACTIVATION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COSTS AND COST ANALYSIS; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL FISTULA; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 33751256840     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2006.09.003     Document Type: Review

References (80)

1. Loftus E.V., and Sandborn W.J. Epidemiology of inflammatory bowel disease. Gastroenterol Clin N Am 31 (2002) 1-20
2. Greenstein A.J., Janowitz H.D., and Sachar D.B. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 55 (1976) 401-412
3. Pizarro T.T., Arseneau K.O., Bamias G., et al. Mouse models for the study of Crohn's disease. Trends Mol Med 9 (2003) 218-222
4. van Deventer S.J. Targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease-the mechanisms of action of infliximab. Aliment Pharmacol Ther 13 Suppl 4 (1999) 3-8
5. Feagan B.G. Maintenance therapy for inflammatory bowel disease. Am J Gastrenterol 98 Suppl 12 (2003) S6-S17
6. Comerford L.W., and Bickston S.J. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol Clin N Am 33 (2004) 387-406
7. Infliximab (Remicade) for Crohn's disease. Med Lett Drugs Ther 41 (1999) 19-20
8. van Deventer S.J. Tumour necrosis factor and Crohn's disease. Gut 40 (1997) 443-448
9. Papadakis K.A., and Targan S.R. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119 (2000) 1148-1157
10. Braegger C.P., Nicholls S., Murch S.H., et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339 (1992) 89-91
11. Murch S.H., Lamkin V.A., Savage M.O., et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32 (1991) 913-917
12. Hadziselimovic F., Emmons L.R., and Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment inflammatory bowel disease. Gut 37 (1995) 260-263
13. Black R.A., Rauch C.T., Kozlosky C.J., et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
14. Moss M.L., Jin S.L., Milla M.E., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-alpha. Nature 385 (1997) 733-736
15. Loetscher H., Schlaeger E.J., Lahm H.W., et al. Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells. J Biol Chem 265 (1990) 20131-20138
16. Heller R.A., and Kronke M. Tumor necrosis factor receptor-mediated signaling pathways. J Cell Biol 126 (1994) 5-9
17. Brett J., Gerlach H., Nawroth P., et al. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 169 (1989) 1977-1991
18. Schutze S., Potthoff K., Machleidt T., et al. TNF activates NFkB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphyngomyelin breakdown. Cell 71 (1992) 765-776
19. Kronke M., Schutze S., Scheurich P., et al. Tumour necrosis factor signal transduction. Cell Signal 2 (1990) 1-8
20. Sandborn W.J., and Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology 122 (2002) 1592-1608
21. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
22. Sandborn W.J. Transcending conventional therapies: the role of biologic and other novel therapies. Inflamm Bowel Dis 1 Suppl 7 (2001) s9-s16
23. Knight D.M., Trinh H., Le J., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30 (1993) 1443-1453
24. Scallon B.J., Moore M.A., Trinh H., et al. Chimeric anti-TNF-alpha monoclonal antibody CA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7 (1995) 251-259
25. Lugering A., Schmidt M., Lugering N., et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
26. Powrie F., Lesch M.W., Mauze S., et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4 + T cells. Immunity 1 (1994) 553-562
27. Derkx B., Taminiau J., Radema S., et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 342 (1993) 173-174
28. van Dullemen H.M., van Deventer S.J., Hommes D.W., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 (1995) 129-135
29. McCabe R.P., Woody J., van Deventer S.J., et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. [abstract]. Gastroenterology 110 Suppl 4 (1996) A962
30. Blam M.E., Stein R.B., and Lichtenstein G.R. Integrity anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 96 (2001) 1977-1997
31. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
32. Hanaeur S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
33. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
34. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
35. Sands B., van Deventer S.J., Bernstein C., et al. Long-term treatment of fistulizing Crohn's disease response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology 122 (2002) 81-82
36. Remicade (infliximab) for IV injection. [package insert] (2003), Centocor, Malvern (PA)
37. Colombel J.F., Loftus E.V., Tremaine W.J., et al. The safety profile of infliximab for Crohn's disease in clinical practice: the Mayo Clinic experience in 500 patients. Gastroenterology 124 (2003) A7
38. Havell E.A. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 143 (1989) 2894-2901
39. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol 49 (1991) 380-387
40. Kindler V., Sappino A.P., Grau G.E., et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56 (1989) 731-740
41. Rook G.A., Taverne J., Leveton C., et al. The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 62 (1987) 229-234
42. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
43. Long R., and Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 168 (2003) 1153-1156
44. Diagnostic standards and classification of tuberculosis in adults and children. Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention, adopted by the American Thoracic Society Board of Directors, July 1999. Endorsed by the Council of the Infectious Diseases Society of America, September 1999. Am J Respir Crit Care Med 161 (2000) 1376-1395
45. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 161 (2000) 1376-1395
46. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3 (2003) 148-155
47. Mow W.S., Abreu M.T., Papadakis K.A., et al. High incidence of anergy limits the usefulness of PPD screening for tuberculosis (TB) prior to Remicade in inflammatory bowel disease (IBD). Gastroenterology 122 (2002) A100
48. Ferrero S., and Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 270 (2004) 79-85
49. Katz J.A., Keenan G.F., Smith D.E., et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Gastroenterology 124 (2003) A63
50. Friedman S., and Regueiro M.D. Pregnancy and nursing inflammatory bowel disease. Gastroenterol Clin N Am 31 (2002) 265-273
51. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
52. Torre-Amione G., Kapadia S., Benedict C., et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
53. Louis A., Cleland J.G., Crabbe S., et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 3 (2001) 381-387
54. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation 107 (2003) 3133
55. Kwon H.J., Cote T.R., Cuffe M.S., et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Inter Med 138 (2003) 807-811
56. Baert F., Noman M., Vermeire G., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
57. Farrell R.J., Alsahli M., Jeen Y.T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 4 (2003) 917-924
58. Sandborn W.J., and Hanauer S.B. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 97 (2002) 2962-2972
59. Hochberg M.C., Lebwohl M.G., Plevy S.E., et al. The benefits/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34 (2005) 819-836
60. Arseneau K.O., Stukenborg G.J., Connors A.F., et al. The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. Inflamm Bowel Dis 7 (2001) 106-112
61. Baecklund E., Ekbom A., Sparen P., et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis nested case-control study. BMJ 317 (1998) 180-181
62. Wasko M.C. Comorbid conditions in patients with rheumatic diseases an update. Curr Opin Rheumatol 16 (2004) 109-113
63. Bickston S.J., Lichtenstein G.R., Arseneau K.O., et al. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 117 (1999) 1433-1437
64. Debandt M., Vittecoq O., Descamps V., et al. Anti-TNF-α induced systemic lupus syndrome. Clin Rheumatol 22 (2003) 56-61
65. Favalli E.G., Sinigaglia L., Varenna M., et al. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 11 (2002) 753-755
66. Ali Y., and Shah S. Infliximab-induced systemic lupus erythematosus. Ann Inter Med 137 (2002) 625-626
67. Mohan N., Edwards E.T., Cupps T.R., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44 (2001) 2862-2869
68. Hanauer S.B., Cohen R.D., Becker R.V., et al. Advances in the management of Crohn's disease economic and clinical potential of infliximab. Clin Ther 20 (1998) 1009-1028
69. Lichtenstein G.R. Incorrect cost of infliximab in Crohn's disease. Gastroenterology 127 (2004) 691-692
70. Rubenstein J.H., Chong R.Y., and Cohen R.D. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 35 (2002) 151-156
71. Lichtenstein G.R., Songkai Y., Mohan B., et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128 (2005) 862-869
72. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
73. Parsi M.A., Achkar J.P., Richardson S., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123 (2002) 707-713
74. Arnott I.D., McNeill G., and Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 15 (2003) 1451-1457
75. Su C., and Lichtenstein G.R. Are there predictors of Remicade treatment success or failure?. Adv Drug Deliv Rev 57 (2005) 237-245
76. Vermeire S., Louis E., Rutgeerts P., et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 123 (2002) 106-111
77. Esters N., Vermeire S., Joossens, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 97 (2002) 1458-1462
78. Sartor R.B. Clinical applications of advances in the genetics of IBD. Rev Gastroenterol Disord 3 Suppl 1 (2003) S9-S17
79. Sandborn W.J., Hanauer S., Loftus E.V., et al. An open label study of human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99 (2004) 1984-1989
80. Papadakis K.A., Shaye O.A., Vasiliauskas E.A., et al. Adalimumab for Crohn's disease with attenuated response to infliximab. Am J Gastroenterol 100 (2005) 75-79